Bladder cancer is a significant global health challenge. Despite advances in surgery and platinum-based chemotherapy over the decades, limited improvements in clinical outcomes have been observed. However, recent years have witnessed the development of immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) that has transformed the therapeutic landscape of bladder cancer across different disease stages. ICIs block inhibitory pathways including PD-1/PD-L1 and CTLA-4 and reawake antitumor immunity, whereas ADCs, the combination of tumor-selective antibodies with potent cytotoxic payloads, ensure targeted cancer cell death with less systemic toxicity. Both therapies have exhibited clinical benefit in bladder cancer individually and in combination. Clinical trials including NIAGARA, CheckMate-274, and EV-302, have defined new perioperative and first-line standards based on ICIs and ADCs. Ongoing advancements in HER2-, Trop-2-, and Nectin-4-directed ADCs, bispecific and small-molecule conjugates, and combination with ICIs are revolutionizing the therapeutic options for bladder cancer. Of note, the combination of an ADC, enfortumab vedotin, with ICI, pembrolizumab, has improved survival in advanced disease scenarios in bladder cancer. Resistance against ICIs and ADCs remains a significant challenge, but identifying predictive biomarkers, integrating molecular profiling with these therapies, and developing effective combination strategies hold strong potential to achieve durable, precise, and personalized treatment outcomes for bladder cancer.
Ibrahim et al. (2025) studied this question.